ArticleCureus2026
Clinical Outcomes and Real-World Effectiveness of Amoxicillin-Clavulanic Acid Across Indian Healthcare Settings: A Retrospective Multicenter Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Amoxicillin-clavulanic acid is one of the most prescribed antimicrobial combinations in India. However, data on its real-world prescribing trends, effectiveness, and safety remain limited. Objective To evaluate prescribing patterns, dosing practices, adjuvant use, clinical effectiveness, and adverse drug reactions (ADRs) associated with Amoxicillin-clavulanic acid across Indian healthcare settings. Methods A retrospective, questionnaire-based multicentric study was conducted using anonymized data from 30,654 patients prescribed Amoxicillin-clavulanic acid under protocol IND/ACL/01. Parameters assessed included demographics, indications, prescriber specialty, dose, duration, adjuvant use, and outcomes. Descriptive statistics were applied. Results Among the analyzed prescriptions, upper respiratory tract infections (52.4%) and lower respiratory tract infections (19.5%) were the most common indications, followed by urinary tract infections (10.0%),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.